Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial

Open access
Caricchio, Roberto, Abbate, Antonio, Gordeev, Ivan, Meng, Jamie, Hsue, Priscilla Y, Neogi, Tuhina, Arduino, Roberto, Fomina, Daria, Bogdanov, Roman, Stepanenko, Tatiana, Ruiz-Seco, Pilar, Gónzalez-García, Andrés, Chen, Yu, Li, Yuhan, Whelan, Sarah, Noviello, Stephanie, CAN-COVID Investigators, Faguer, Stanislas, Papi, Alberto, Di Marco, Fabiano, Agafina, Alina S., Mochalova, Anastasia S., Lioznov, Dmitry A., Privalov, Dmitry V., Trufanov, Konstantin V., Martynenko, Tatiana I., Pablos-Alvarez, José Luis, Bujan, Segundo, Estrada, Vicente, Solanich-Moreno, Xavier, Randeva, Harpal, Tahir, Hasan, Lachmann, Helen J., Savic, Sinisa, Patel, Vishal, Lachiewicz, Anne, Taiwo, Babafemi, Kuritzkes, Daniel R., Jacobson, Jeffrey M., Chua, Joel V., Shirinian, Mihran, Fung, Monica, Overton, Turner, Malhotra, Vinay, Kissin, Eugene, Morone, Natalia, Sagar, Manish, Trojanowski, Marcin, Desai, Parag, Krachman, Samuel, Salerno, Daniel, Stewart, Jeffrey, Zheng, Matthew, Gupta, Rohit, Shenoy, Kartik, Marchetti, Nathaniel, Patel, Maulin, Jaffe, Fredric, Chowdhury, Junad, Brown, James, Vega-Sanchez, Maria Elena, Codella, Stephen, Verga, Steven, Fernandez-Romero, Gustavo, Mokha, Janpreet, Criner, Gerard J., Rali, Parth, Sehgal, Sameep, Dorey-Stein, Zachariah, Satti, Aditi, Dominguez-Castillo, Eduardo, Mills, Nicole, Mamary, Albert J., Gangemi, Andrew, Shani, Jacob, Frankel, Robert, Sharma, Kavita, Malyshev, Yury, Brady, Jason, Christian, Manan, Tan-Augenstein, Gwendolyn, Chiandussi, Damian A., Behne, Ann, Black, Mellisa, Bonaventura, Aldo, Earl Clary, Rick, Deutsch, Henley, Duke, Christina, Greer, Joan, Hardin, Mary, Harmon, Mary, Kemp, Heather, Ho, Ai-Chen, Ibe, Ikenna, Ladd, Amy, Marawan, Amr, Markley, Roshanak, McKee, Kim, Mihalick, Virginia, Montpetit, Alison, Mbualungu, James, O’Brien, Joyce, Owen, Catherine, Pak, Mary, Patel, Nimesh, Payne, William, Priday, Anna, Sculthorpe, Robin, Sears, Melissa, Sedhai, Yub Raj, Sims, Earl Kenneth, Spence, Kathryn, Tackett, Hilary, Thomas, Georgia, Turner, Juanita, Van Tassell, Benjamin, Vecchiè, Alessandra, Wohlford, George·2021·JAMA

Abstract

Importance: Effective treatments for patients with severe COVID-19 are needed. Objective: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. Intervention: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227). Main Outcomes and Measures: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. Results: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. Conclusions and Relevance: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. Trial Registration: ClinicalTrials.gov Identifier: NCT04362813.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2021.9508

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 164

Metadata

Authors
Caricchio, R., Abbate, A., Gordeev, I., Meng, J., Hsue, P. Y., Neogi, T., Arduino, R., Fomina, D., Bogdanov, R., Stepanenko, T., Ruiz-Seco, P., Gónzalez-García, A., Chen, Y., Li, Y., Whelan, S., Noviello, S., CAN-COVID Investigators, Faguer, S., Papi, A., Di Marco, F., Agafina, A. S., Mochalova, A. S., Lioznov, D. A., Privalov, D. V., Trufanov, K. V., Martynenko, T. I., Pablos-Alvarez, J. L., Bujan, S., Estrada, V., Solanich-Moreno, X., Randeva, H., Tahir, H., Lachmann, H. J., Savic, S., Patel, V., Lachiewicz, A., Taiwo, B., Kuritzkes, D. R., Jacobson, J. M., Chua, J. V., Shirinian, M., Fung, M., Overton, T., Malhotra, V., Kissin, E., Morone, N., Sagar, M., Trojanowski, M., Desai, P., Krachman, S., Salerno, D., Stewart, J., Zheng, M., Gupta, R., Shenoy, K., Marchetti, N., Patel, M., Jaffe, F., Chowdhury, J., Brown, J., Vega-Sanchez, M. E., Codella, S., Verga, S., Fernandez-Romero, G., Mokha, J., Criner, G. J., Rali, P., Sehgal, S., Dorey-Stein, Z., Satti, A., Dominguez-Castillo, E., Mills, N., Mamary, A. J., Gangemi, A., Shani, J., Frankel, R., Sharma, K., Malyshev, Y., Brady, J., Christian, M., Tan-Augenstein, G., Chiandussi, D. A., Behne, A., Black, M., Bonaventura, A., Earl Clary, R., Deutsch, H., Duke, C., Greer, J., Hardin, M., Harmon, M., Kemp, H., Ho, A.-C., Ibe, I., Ladd, A., Marawan, A., Markley, R., McKee, K., Mihalick, V., Montpetit, A., Mbualungu, J., O’Brien, J., Owen, C., Pak, M., Patel, N., Payne, W., Priday, A., Sculthorpe, R., Sears, M., Sedhai, Y. R., Sims, E. K., Spence, K., Tackett, H., Thomas, G., Turner, J., Van Tassell, B., Vecchiè, A., & Wohlford, G.
Venue
JAMA
Published
2021-07-20
Volume
326
Issue
3
Pages
230
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W3183356099
Cited by
164
References
5
FWCI
11.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2021.9508
The paper
Caricchio, R., Abbate, A., Gordeev, I., Meng, J., Hsue, P. Y., Neogi, T., Arduino, R., Fomina, D., Bogdanov, R., Stepanenko, T., Ruiz-Seco, P., Gónzalez-García, A., Chen, Y., Li, Y., Whelan, S., Noviello, S., CAN-COVID Investigators, Faguer, S., Papi, A., . . . Wohlford, G. (2021). Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2021.9508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.